- Home
- RBOT vs MNOV Comparison
RBOT vs MNOV Comparison
Compare RBOT & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RBOT | MNOV |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1M | 72.7M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | RBOT | MNOV |
|---|---|---|
| Price | $1.85 | $1.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $7.00 | $7.00 |
| AVG Volume (30 Days) | ★ 164.0K | 80.3K |
| Earning Date | 11-12-2025 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $257,917.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.83 | $1.13 |
| 52 Week High | $18.97 | $2.20 |
Technical Indicators
Market Signals| Indicator | RBOT | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 24.87 | 35.08 |
| Support Level | $2.16 | $1.23 |
| Resistance Level | $2.33 | $1.51 |
| Average True Range (ATR) | 0.20 | 0.05 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 0.81 | 16.18 |
Price Performance
Historical ComparisonAbout RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's strategies are to focus its developing activities on therapeutics for neurological disorders and fibrotic diseases.